Skip to main content
Erschienen in: Current Hepatology Reports 4/2018

24.10.2018 | Hepatic Cancer (A Singal and A Mufti, Section Editors)

LI-RADS v2018: a Primer and Update for Clinicians

Erschienen in: Current Hepatology Reports | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

To familiarize readers with recent updates and additions to the Liver Imaging and Reporting Data System (LI-RADS) v2018 for hepatocellular carcinoma surveillance, diagnosis, and treatment response assessment.

Recent Findings

US surveillance, diagnosis, and treatment response assessment algorithms are now incorporated into LI-RADS v2018. Updates to the diagnostic algorithm for CT and MRI include clarification of the LI-RADS appropriate population, revision of LR-5 criteria to match with those advocated by the American Association for Study of Liver Disease, new specific criteria for the LR-M category, and modification of the tumor in vein (TIV) category.

Summary

LI-RADS v2018 facilitates clear communication between radiologists and the rest of the health care team by standardizing imaging terminology, interpretation, and reporting. LI-RADS also enhances imaging quality by providing minimal technical requirements for hepatocellular carcinoma imaging. Recent updates address US surveillance, clarify terminology, and incorporate treatment response. With these updates, LI-RADS addresses the entire spectrum of hepatocellular carcinoma imaging from screening to treatment response, thereby further promoting its integration into practice.
Literatur
1.
Zurück zum Zitat Elsayes KM, Kielar AZ, Agrons MM, Szklaruk J, Tang A, Bashir MR, et al. Liver imaging reporting and data system: an expert consensus statement. J Hepatocell Carcinoma. 2017;4:29–39.CrossRef Elsayes KM, Kielar AZ, Agrons MM, Szklaruk J, Tang A, Bashir MR, et al. Liver imaging reporting and data system: an expert consensus statement. J Hepatocell Carcinoma. 2017;4:29–39.CrossRef
2.
Zurück zum Zitat Radiology, A.C.O Liver imaging reporting and data systems (LI-RADS) v 2018 core. 2017 12–2017 [cited 2018 01–29-18]; Available from: (https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/LI-RADS/CT-MRI-LI-RADS-v2018). Radiology, A.C.O Liver imaging reporting and data systems (LI-RADS) v 2018 core. 2017 12–2017 [cited 2018 01–29-18]; Available from: (https://​www.​acr.​org/​Clinical-Resources/​Reporting-and-Data-Systems/​LI-RADS/​CT-MRI-LI-RADS-v2018).
3.
Zurück zum Zitat Aube C, et al. EASL and AASLD recommendations for the diagnosis of HCC to the test of daily practice. Liver Int. 2017;37(10):1515–25.CrossRef Aube C, et al. EASL and AASLD recommendations for the diagnosis of HCC to the test of daily practice. Liver Int. 2017;37(10):1515–25.CrossRef
4.
Zurück zum Zitat Wald C, Russo MW, Heimbach JK, Hussain HK, Pomfret EA, Bruix J. New OPTN/UNOS policy for liver transplant allocation: standardization of liver imaging, diagnosis, classification, and reporting of hepatocellular carcinoma. Radiology. 2013;266(2):376–82.CrossRef Wald C, Russo MW, Heimbach JK, Hussain HK, Pomfret EA, Bruix J. New OPTN/UNOS policy for liver transplant allocation: standardization of liver imaging, diagnosis, classification, and reporting of hepatocellular carcinoma. Radiology. 2013;266(2):376–82.CrossRef
5.
Zurück zum Zitat Heimbach JK. Overview of the updated AASLD guidelines for the management of HCC. Gastroenterol Hepatol (N Y). 2017;13(12):751–3. Heimbach JK. Overview of the updated AASLD guidelines for the management of HCC. Gastroenterol Hepatol (N Y). 2017;13(12):751–3.
6.
Zurück zum Zitat Benson AB 3rd. Hepatobiliary cancer. Clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2003;1(1):94–108.CrossRef Benson AB 3rd. Hepatobiliary cancer. Clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2003;1(1):94–108.CrossRef
7.
Zurück zum Zitat Tang A, Hallouch O, Chernyak V, Kamaya A, Sirlin CB. Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis. Abdom Radiol (NY). 2018;43(1):13–25.CrossRef Tang A, Hallouch O, Chernyak V, Kamaya A, Sirlin CB. Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis. Abdom Radiol (NY). 2018;43(1):13–25.CrossRef
8.
Zurück zum Zitat Morgan TA, et al. US LI-RADS: ultrasound liver imaging reporting and data system for screening and surveillance of hepatocellular carcinoma. Abdom Radiol (NY). 2018;43(1):41–55.CrossRef Morgan TA, et al. US LI-RADS: ultrasound liver imaging reporting and data system for screening and surveillance of hepatocellular carcinoma. Abdom Radiol (NY). 2018;43(1):41–55.CrossRef
9.
Zurück zum Zitat Simmons O, Fetzer DT, Yokoo T, Marrero JA, Yopp A, Kono Y, et al. Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis. Aliment Pharmacol Ther. 2017;45(1):169–77.CrossRef Simmons O, Fetzer DT, Yokoo T, Marrero JA, Yopp A, Kono Y, et al. Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis. Aliment Pharmacol Ther. 2017;45(1):169–77.CrossRef
10.
Zurück zum Zitat Singal A, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009;30(1):37–47.CrossRef Singal A, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009;30(1):37–47.CrossRef
11.
Zurück zum Zitat Tzartzeva K, et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology. 2018;154(6):1706–18 e1.CrossRef Tzartzeva K, et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology. 2018;154(6):1706–18 e1.CrossRef
12.
Zurück zum Zitat Marks RM, Ryan A, Heba ER, Tang A, Wolfson TJ, Gamst AC, et al. Diagnostic per-patient accuracy of an abbreviated hepatobiliary phase gadoxetic acid-enhanced MRI for hepatocellular carcinoma surveillance. AJR Am J Roentgenol. 2015;204(3):527–35.CrossRef Marks RM, Ryan A, Heba ER, Tang A, Wolfson TJ, Gamst AC, et al. Diagnostic per-patient accuracy of an abbreviated hepatobiliary phase gadoxetic acid-enhanced MRI for hepatocellular carcinoma surveillance. AJR Am J Roentgenol. 2015;204(3):527–35.CrossRef
13.
Zurück zum Zitat Besa C, Lewis S, Pandharipande PV, Chhatwal J, Kamath A, Cooper N, et al. Hepatocellular carcinoma detection: diagnostic performance of a simulated abbreviated MRI protocol combining diffusion-weighted and T1-weighted imaging at the delayed phase post gadoxetic acid. Abdom Radiol (NY). 2017;42(1):179–90.CrossRef Besa C, Lewis S, Pandharipande PV, Chhatwal J, Kamath A, Cooper N, et al. Hepatocellular carcinoma detection: diagnostic performance of a simulated abbreviated MRI protocol combining diffusion-weighted and T1-weighted imaging at the delayed phase post gadoxetic acid. Abdom Radiol (NY). 2017;42(1):179–90.CrossRef
14.
Zurück zum Zitat Goossens N, Singal AG, King LY, Andersson KL, Fuchs BC, Besa C, et al. Cost-effectiveness of risk score-stratified hepatocellular carcinoma screening in patients with cirrhosis. Clin Transl Gastroenterol. 2017;8(6):e101.CrossRef Goossens N, Singal AG, King LY, Andersson KL, Fuchs BC, Besa C, et al. Cost-effectiveness of risk score-stratified hepatocellular carcinoma screening in patients with cirrhosis. Clin Transl Gastroenterol. 2017;8(6):e101.CrossRef
15.
Zurück zum Zitat • Fraum TJ, et al. Differentiation of hepatocellular carcinoma from other hepatic malignancies in patients at risk: diagnostic performance of the liver imaging reporting and data system version 2014. Radiology. 2018;286(1):158–72 Single-center retrospective study with pathological reference standard, evaluated the features of non-HCC malignancies in an at risk cohort to help define LR-M and TIV criteria for v2017. CrossRef • Fraum TJ, et al. Differentiation of hepatocellular carcinoma from other hepatic malignancies in patients at risk: diagnostic performance of the liver imaging reporting and data system version 2014. Radiology. 2018;286(1):158–72 Single-center retrospective study with pathological reference standard, evaluated the features of non-HCC malignancies in an at risk cohort to help define LR-M and TIV criteria for v2017. CrossRef
16.
Zurück zum Zitat Fowler KJ, Potretzke TA, Hope TA, Costa EA, Wilson SR. LI-RADS M (LR-M): definite or probable malignancy, not specific for hepatocellular carcinoma. Abdom Radiol (NY). 2018;43(1):149–57.CrossRef Fowler KJ, Potretzke TA, Hope TA, Costa EA, Wilson SR. LI-RADS M (LR-M): definite or probable malignancy, not specific for hepatocellular carcinoma. Abdom Radiol (NY). 2018;43(1):149–57.CrossRef
17.
Zurück zum Zitat Santillan C, Chernyak V, Sirlin C. LI-RADS categories: concepts, definitions, and criteria. Abdom Radiol (NY). 2018;43(1):101–10.CrossRef Santillan C, Chernyak V, Sirlin C. LI-RADS categories: concepts, definitions, and criteria. Abdom Radiol (NY). 2018;43(1):101–10.CrossRef
18.
Zurück zum Zitat Santillan C, Fowler K, Kono Y, Chernyak V. LI-RADS major features: CT, MRI with extracellular agents, and MRI with hepatobiliary agents. Abdom Radiol (NY). 2018;43(1):75–81.CrossRef Santillan C, Fowler K, Kono Y, Chernyak V. LI-RADS major features: CT, MRI with extracellular agents, and MRI with hepatobiliary agents. Abdom Radiol (NY). 2018;43(1):75–81.CrossRef
19.
Zurück zum Zitat Chernyak V, Santillan CS, Papadatos D, Sirlin CB. LI-RADS((R)) algorithm: CT and MRI. Abdom Radiol (NY). 2018;43(1):111–26.CrossRef Chernyak V, Santillan CS, Papadatos D, Sirlin CB. LI-RADS((R)) algorithm: CT and MRI. Abdom Radiol (NY). 2018;43(1):111–26.CrossRef
20.
Zurück zum Zitat Chernyak V, Tang A, Flusberg M, Papadatos D, Bijan B, Kono Y, et al. LI-RADS((R)) ancillary features on CT and MRI. Abdom Radiol (NY). 2018;43(1):82–100.CrossRef Chernyak V, Tang A, Flusberg M, Papadatos D, Bijan B, Kono Y, et al. LI-RADS((R)) ancillary features on CT and MRI. Abdom Radiol (NY). 2018;43(1):82–100.CrossRef
21.
Zurück zum Zitat CORE, A.L.R. 2017; Available from: chrome-extension://oemmndcbldboiebfnladdacbdfmadadm/https://www.acr.org/-/media/ACR/Files/RADS/LI-RADS/LIRADS_2017_Core.pdf?la=en. CORE, A.L.R. 2017; Available from: chrome-extension://oemmndcbldboiebfnladdacbdfmadadm/https://​www.​acr.​org/​-/​media/​ACR/​Files/​RADS/​LI-RADS/​LIRADS_​2017_​Core.​pdf?​la=​en.​
22.
Zurück zum Zitat •• Tang A, et al. Evidence supporting LI-RADS major features for CT- and MR imaging-based diagnosis of hepatocellular carcinoma: a systematic review. Radiology. 2018;286(1):29–48 Systematic review that captures current evidence supporting LI-RADS major features and categories. CrossRef •• Tang A, et al. Evidence supporting LI-RADS major features for CT- and MR imaging-based diagnosis of hepatocellular carcinoma: a systematic review. Radiology. 2018;286(1):29–48 Systematic review that captures current evidence supporting LI-RADS major features and categories. CrossRef
23.
Zurück zum Zitat Zhang YD, Zhu FP, Xu X, Wang Q, Wu CJ, Liu XS, et al. Liver imaging reporting and data system: substantial discordance between CT and MR for imaging classification of hepatic nodules. Acad Radiol. 2016;23(3):344–52.CrossRef Zhang YD, Zhu FP, Xu X, Wang Q, Wu CJ, Liu XS, et al. Liver imaging reporting and data system: substantial discordance between CT and MR for imaging classification of hepatic nodules. Acad Radiol. 2016;23(3):344–52.CrossRef
24.
Zurück zum Zitat Fowler KJ, Tang A, Santillan C, Bhargavan-Chatfield M, Heiken J, Jha RC, et al. Interreader reliability of LI-RADS version 2014 algorithm and imaging features for diagnosis of hepatocellular carcinoma: a large international multireader study. Radiology. 2018;286(1):173–85.CrossRef Fowler KJ, Tang A, Santillan C, Bhargavan-Chatfield M, Heiken J, Jha RC, et al. Interreader reliability of LI-RADS version 2014 algorithm and imaging features for diagnosis of hepatocellular carcinoma: a large international multireader study. Radiology. 2018;286(1):173–85.CrossRef
25.
Zurück zum Zitat Davenport MS, Khalatbari S, Liu PSC, Maturen KE, Kaza RK, Wasnik AP, et al. Repeatability of diagnostic features and scoring systems for hepatocellular carcinoma by using MR imaging. Radiology. 2014;272(1):132–42.CrossRef Davenport MS, Khalatbari S, Liu PSC, Maturen KE, Kaza RK, Wasnik AP, et al. Repeatability of diagnostic features and scoring systems for hepatocellular carcinoma by using MR imaging. Radiology. 2014;272(1):132–42.CrossRef
26.
Zurück zum Zitat Becker AS, Barth BK, Marquez PH, Donati OF, Ulbrich EJ, Karlo C, et al. Increased interreader agreement in diagnosis of hepatocellular carcinoma using an adapted LI-RADS algorithm. Eur J Radiol. 2017;86:33–40.CrossRef Becker AS, Barth BK, Marquez PH, Donati OF, Ulbrich EJ, Karlo C, et al. Increased interreader agreement in diagnosis of hepatocellular carcinoma using an adapted LI-RADS algorithm. Eur J Radiol. 2017;86:33–40.CrossRef
27.
Zurück zum Zitat Ehman EC, Behr SC, Umetsu SE, Fidelman N, Yeh BM, Ferrell LD, et al. Rate of observation and inter-observer agreement for LI-RADS major features at CT and MRI in 184 pathology proven hepatocellular carcinomas. Abdom Radiol (NY). 2016;41(5):963–9.CrossRef Ehman EC, Behr SC, Umetsu SE, Fidelman N, Yeh BM, Ferrell LD, et al. Rate of observation and inter-observer agreement for LI-RADS major features at CT and MRI in 184 pathology proven hepatocellular carcinomas. Abdom Radiol (NY). 2016;41(5):963–9.CrossRef
28.
Zurück zum Zitat Sofue K, Sirlin CB, Allen BC, Nelson RC, Berg CL, Bashir MR. How reader perception of capsule affects interpretation of washout in hypervascular liver nodules in patients at risk for hepatocellular carcinoma. J Magn Reson Imaging. 2016;43(6):1337–45.CrossRef Sofue K, Sirlin CB, Allen BC, Nelson RC, Berg CL, Bashir MR. How reader perception of capsule affects interpretation of washout in hypervascular liver nodules in patients at risk for hepatocellular carcinoma. J Magn Reson Imaging. 2016;43(6):1337–45.CrossRef
29.
Zurück zum Zitat Bashir MR, Huang R, Mayes N, Marin D, Berg CL, Nelson RC, et al. Concordance of hypervascular liver nodule characterization between the organ procurement and transplant network and liver imaging reporting and data system classifications. J Magn Reson Imaging. 2015;42(2):305–14.CrossRef Bashir MR, Huang R, Mayes N, Marin D, Berg CL, Nelson RC, et al. Concordance of hypervascular liver nodule characterization between the organ procurement and transplant network and liver imaging reporting and data system classifications. J Magn Reson Imaging. 2015;42(2):305–14.CrossRef
30.
Zurück zum Zitat Choi, M.H., Park G.E., Oh S.N., Park M.Y., Rha S.E., Lee Y.J., Jung S.E., Choi J.I., Reproducibility of mRECIST in measurement and response assessment for hepatocellular carcinoma treated by transarterial chemoembolization. Acad Radiol, 2018. Choi, M.H., Park G.E., Oh S.N., Park M.Y., Rha S.E., Lee Y.J., Jung S.E., Choi J.I., Reproducibility of mRECIST in measurement and response assessment for hepatocellular carcinoma treated by transarterial chemoembolization. Acad Radiol, 2018.
31.
Zurück zum Zitat Lencioni R, Montal R, Torres F, Park JW, Decaens T, Raoul JL, et al. Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC. J Hepatol. 2017;66(6):1166–72.CrossRef Lencioni R, Montal R, Torres F, Park JW, Decaens T, Raoul JL, et al. Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC. J Hepatol. 2017;66(6):1166–72.CrossRef
32.
Zurück zum Zitat • Ronot M, et al. Comparison of the accuracy of AASLD and LI-RADS criteria for the non-invasive diagnosis of HCC smaller than 3cm. J Hepatol. 2017; Prospective study comparing diagnostic accuracy of AASLD and LI-RADS in at-risk cohort, helps establish high PPV/specificity for LR-5 criteria. • Ronot M, et al. Comparison of the accuracy of AASLD and LI-RADS criteria for the non-invasive diagnosis of HCC smaller than 3cm. J Hepatol. 2017; Prospective study comparing diagnostic accuracy of AASLD and LI-RADS in at-risk cohort, helps establish high PPV/specificity for LR-5 criteria.
33.
Zurück zum Zitat Kim YY, An C, Kim S, Kim MJ. Diagnostic accuracy of prospective application of the liver imaging reporting and data system (LI-RADS) in gadoxetate-enhanced MRI. Eur Radiol. 2018;28(5):2038–46.CrossRef Kim YY, An C, Kim S, Kim MJ. Diagnostic accuracy of prospective application of the liver imaging reporting and data system (LI-RADS) in gadoxetate-enhanced MRI. Eur Radiol. 2018;28(5):2038–46.CrossRef
34.
Zurück zum Zitat Choi SH, et al. Liver imaging reporting and data system v2014 with gadoxetate disodium-enhanced magnetic resonance imaging: validation of LI-RADS category 4 and 5 criteria. Investig Radiol. 2016;51(8):483–90.CrossRef Choi SH, et al. Liver imaging reporting and data system v2014 with gadoxetate disodium-enhanced magnetic resonance imaging: validation of LI-RADS category 4 and 5 criteria. Investig Radiol. 2016;51(8):483–90.CrossRef
35.
Zurück zum Zitat Darnell A, Forner A, Rimola J, Reig M, García-Criado Á, Ayuso C, et al. Liver imaging reporting and data system with MR imaging: evaluation in nodules 20 mm or smaller detected in cirrhosis at screening US. Radiology. 2015;275(3):698–707.CrossRef Darnell A, Forner A, Rimola J, Reig M, García-Criado Á, Ayuso C, et al. Liver imaging reporting and data system with MR imaging: evaluation in nodules 20 mm or smaller detected in cirrhosis at screening US. Radiology. 2015;275(3):698–707.CrossRef
36.
Zurück zum Zitat Cerny M, et al. LI-RADS for MR imaging diagnosis of hepatocellular carcinoma: performance of major and ancillary features. Radiology. 2018:171678. Cerny M, et al. LI-RADS for MR imaging diagnosis of hepatocellular carcinoma: performance of major and ancillary features. Radiology. 2018:171678.
37.
Zurück zum Zitat Tanabe M, et al. Imaging outcomes of liver imaging reporting and data system version 2014 category 2, 3, and 4 observations detected at CT and MR imaging. Radiology. 2016;281(1):129–39.CrossRef Tanabe M, et al. Imaging outcomes of liver imaging reporting and data system version 2014 category 2, 3, and 4 observations detected at CT and MR imaging. Radiology. 2016;281(1):129–39.CrossRef
38.
Zurück zum Zitat Choi JY, Cho HC, Sun M, Kim HC, Sirlin CB. Indeterminate observations (liver imaging reporting and data system category 3) on MRI in the cirrhotic liver: fate and clinical implications. AJR Am J Roentgenol. 2013;201(5):993–1001.CrossRef Choi JY, Cho HC, Sun M, Kim HC, Sirlin CB. Indeterminate observations (liver imaging reporting and data system category 3) on MRI in the cirrhotic liver: fate and clinical implications. AJR Am J Roentgenol. 2013;201(5):993–1001.CrossRef
39.
Zurück zum Zitat Burke LM, et al. Natural history of liver imaging reporting and data system category 4 nodules in MRI. Abdom Radiol (NY). 2016;41(9):1758–66.CrossRef Burke LM, et al. Natural history of liver imaging reporting and data system category 4 nodules in MRI. Abdom Radiol (NY). 2016;41(9):1758–66.CrossRef
40.
Zurück zum Zitat An C, Park S, Chung YE, Kim DY, Kim SS, Kim MJ, et al. Curative resection of single primary hepatic malignancy: liver imaging reporting and data system category LR-M portends a worse prognosis. AJR Am J Roentgenol. 2017;209(3):576–83.CrossRef An C, Park S, Chung YE, Kim DY, Kim SS, Kim MJ, et al. Curative resection of single primary hepatic malignancy: liver imaging reporting and data system category LR-M portends a worse prognosis. AJR Am J Roentgenol. 2017;209(3):576–83.CrossRef
41.
Zurück zum Zitat Joo I, Lee JM, Lee SM, Lee JS, Park JY, Han JK. Diagnostic accuracy of liver imaging reporting and data system (LI-RADS) v2014 for intrahepatic mass-forming cholangiocarcinomas in patients with chronic liver disease on gadoxetic acid-enhanced MRI. J Magn Reson Imaging. 2016;44(5):1330–8.CrossRef Joo I, Lee JM, Lee SM, Lee JS, Park JY, Han JK. Diagnostic accuracy of liver imaging reporting and data system (LI-RADS) v2014 for intrahepatic mass-forming cholangiocarcinomas in patients with chronic liver disease on gadoxetic acid-enhanced MRI. J Magn Reson Imaging. 2016;44(5):1330–8.CrossRef
Metadaten
Titel
LI-RADS v2018: a Primer and Update for Clinicians
Publikationsdatum
24.10.2018
Erschienen in
Current Hepatology Reports / Ausgabe 4/2018
Elektronische ISSN: 2195-9595
DOI
https://doi.org/10.1007/s11901-018-0441-7

Weitere Artikel der Ausgabe 4/2018

Current Hepatology Reports 4/2018 Zur Ausgabe

Portal Hypertension (J Gonzalez-Abraldes and E Tsochatzis, Section Editors)

Small Esophageal Varices in Patients with Cirrhosis—Should We Treat Them?

Hepatic Cancer (A Singal and A Mufti, Section Editors)

Current State of Immunotherapy for HCC—Supporting Data and Toxicity Management

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.